TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
BIO-TECHNE Corp revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $874.62M | $870.25M | $830.90M | $845.75M | $832.31M | $704.56M | $555.35M | $543.16M | $482.38M | $419.37M | 72.0% | +0.5% |
| Diagnostics and Spatial Biology | $336.37M | $346.26M | $326.39M | $292.60M | – | – | – | – | – | – | 27.7% | -2.9% |
| Biotechnology [Member] | – | – | – | – | – | – | – | – | $421.54M | $364.50M | – | – |
| Protein Platforms [Member] | – | – | – | – | – | – | – | – | $111.89M | $91.46M | – | – |
| Diagnostics [Member] | – | – | – | – | – | – | – | – | $110.11M | $107.14M | – | – |
| Diagnostics and Genomics | – | – | $326.39M | $292.60M | $274.84M | $227.74M | $184.55M | $171.67M | $161.15M | $143.74M | – | – |
| Other Revenues from Business Held for Sale | – | – | $4.15M | – | – | – | – | – | – | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $359.40M | $370.35M | $354.78M | $373.68M | $377.62M | $330.23M | $234.93M | $240.92M | $209.88M | $184.10M | -3.0% |
| Diagnostics and Spatial Biology | $37.70M | $21.32M | $24.55M | $43.04M | – | – | – | – | – | – | +76.8% |
| Biotechnology [Member] | – | – | – | – | – | – | – | – | $199.10M | $175.16M | – |
| Protein Platforms [Member] | – | – | – | – | – | – | – | – | $18.00M | $9.65M | – |
| Diagnostics [Member] | – | – | – | – | – | – | – | – | $28.28M | $28.58M | – |
| Diagnostics and Genomics | – | – | $24.55M | $43.04M | $48.98M | $38.43M | $14.97M | $10.08M | $35.50M | $29.29M | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Services | $1.19B | $1.20B | $1.14B | $1.12B | $1.08B | $912.18M | $721.56M | $694.57M | $630.66M | $547.94M | 97.9% | -0.5% |
| Consumables | $985.12M | $972.29M | $928.18M | $917.73M | $890.87M | $751.99M | $602.64M | $588.98M | $534.74M | $476.54M | 81.1% | +1.3% |
| Instruments | $110.63M | $112.09M | $108.27M | $112.09M | $120.76M | $93.78M | $71.46M | $67.54M | $61.78M | $47.75M | 9.1% | -1.3% |
| Services | $94.30M | $111.57M | $99.27M | $85.78M | $71.99M | $66.42M | $47.46M | $38.05M | $34.14M | $23.65M | 7.8% | -15.5% |
| Royalty revenues | $24.99M | $23.69M | $23.35M | $21.10M | $21.98M | $18.85M | $17.13M | $19.44M | $12.33M | $15.06M | 2.1% | +5.5% |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $635.37M | $683.23M | $657.75M | $642.47M | $614.11M | $502.08M | $404.41M | $391.19M | $346.29M | $313.20M | 52.3% | -7.0% |
| EMEA, excluding United Kingdom | $294.22M | $266.31M | $241.43M | $220.23M | $219.06M | $204.26M | $155.29M | $155.82M | $148.60M | $125.13M | 24.2% | +10.5% |
| China | $104.06M | $100.46M | $99.47M | $113.87M | $112.44M | $87.56M | $68.79M | $57.80M | $47.95M | $39.08M | 8.6% | +3.6% |
| APAC, excluding Greater China | $85.82M | $77.26M | $73.90M | $73.19M | $76.14M | $69.01M | $60.36M | $52.91M | $48.39M | $41.46M | 7.1% | +11.1% |
| United Kingdom | $56.28M | $54.83M | $50.01M | $49.46M | $48.64M | $40.95M | $30.41M | $34.98M | $33.70M | $28.40M | 4.6% | +2.7% |
| Rest of World | $39.29M | $37.55M | $36.50M | $37.49M | $35.22M | $27.17M | $19.43M | $21.31M | $18.06M | $15.74M | 3.2% | +4.6% |
From the segment and revenue-disaggregation notes of Bio-Techne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.